Experts review how the treatment landscape for relapsed/refractory multiple myeloma shifted with the addition of bispecifics, and the currently approved bispecifics available.
Evolving Treatment Paradigm for Relapsed Refractory Multiple Myeloma
Key opinion leaders discuss how bispecifics are administered at their institutions.
Caitlin Costello, MD, shares her thoughts on administering teclistamab to patients with relapsed/refractory multiple myeloma in an outpatient setting.
Matthew Pianko, MD, explains how patients with relapsed/refractory multiple myeloma are monitored for CRS and ICANS.
Experts discuss key data on the outpatient management of teclistamab.
Drs Costello and Pianko close their discussion by sharing advice for clinicians administering bispecifics to their patients with relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
3
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
4
TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)
5